Skip to main content
Stephen Smith, MD, Hematology, Seattle, WA

Stephen Douglas Smith MD

Hematology•Seattle, WA

Associate Professor, Fred Hutchinson Cancer Center

Join to view full profile

  • 825 Eastlake Ave E # G3-200Seattle, WA 98109

  • Phone+1 206-606-6832

  • Fax+1 206-606-6831

Dr. Smith is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Smith's full profileAlready have an account?

Summary

  • Dr. Stephen Smith is a hematologist based in Seattle, WA, with a comprehensive background in immunotherapy, lymphoma, stem cell transplantation, and CAR T-cell therapy. He completed his residency in Internal Medicine at USC/LA General, and his fellowship in Hematology and Medical Oncology at Cleveland Clinic Foundation. His research contributions include several publications on lymphoma and hematologic malignancies. Dr. Smith has served as a principal investigator in numerous clinical trials related to B-cell malignancies and lymphoma.

Clinical Expertise

  • Immunotherapy, Lymphoma, Stem cell transplantation, CAR T-cell Therapy

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2005 - 2008
  • University of Southern California/Los Angeles General Medical Center (USC/LA General)
    University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2002 - 2005
  • Keck School of Medicine of the University of Southern California
    Keck School of Medicine of the University of Southern CaliforniaClass of 2002

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2003 - Present
  • OR State Medical License
    OR State Medical License 2011 - Present
  • WA State Medical License
    WA State Medical License 2013 - 2028
  • OH State Medical License
    OH State Medical License 2005 - 2012
  • Hematology
    American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  
    Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

  • A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
    Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
    Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
    Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Authored Content

  • Mantle Cell Lymphoma at ASH 2022 – More Answers, and More QuestionsDecember 2022

Press Mentions

  • SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual Meeting
    SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Stephen Smith, Dr. Stephen Smith, MD, Dr. S Smith, Dr. Stephen Douglas Smith